AMY SEHNERT, MD, is VP, head of cardiomyopathy and heart failure clinical development at Bristol Myers Squibb in California. She is a passionate physician executive advancing science from bench-to-bedside. Through a precision approach targeting molecular-genetic underpinnings of serious cardiovascular diseases, Sehnert and her team work diligently to identify, optimize, and develop therapies addressing unmet needs. She led her team through regulatory filings and the approval of Camzyos®, the first and only FDA-approved cardiac myosin inhibitor. Sehnert is recognized in San Francisco as an Influential Woman in Business and named a top 25 healthcare technology leader by The Healthcare Technology Report.